皮肤科

以下为当前的临床试验。

按位置、状态和其他条件筛选该研究列表。

1. A Study to Collect Long-Term Data on Pediatric Cutaneous Mastocytosis

   Rochester, Minn.

   The purpose of this study is to develop a registry to collect long-term data on patients with pediatric cutaneous mastocytosis, and develop better knowledge of the timing, symptoms, resolution or progression of the disease, and predictive markers of its severity.

2. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

3. A 2-stage, Phase III Study To Investigate The Efficacy And Safety Of Anifrolumab In Adults With Chronic And/​or Subacute Cutaneous Lupus Erythematosus (LAVENDER)

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

4. Predictors of Inflammatory Arthritis in Patients with Hidradenitis Suppurativa and Psoriasis

   Rochester, Minn.

   The purpose of this study is to identify the incidence and prevalence of inflammatory arthritis in patients with Hidradenitis Suppurativa (HS) and compare them with those in patients with psoriasis through implementing a routine screening. Identifying the incidence and prevalence of this comorbidity has the potential to increase awareness across the specialties of rheumatology and comorbid diseases.

   The aims of this study are to determine the frequency, severity, and duration of symptoms of arthritis in patients with HS and compare them with those in patients with psoriasis, to determine the association between inflammatory arthritis and disease flare-ups/severity in HS, to investigate impact of inflammatory arthritis on the quality of life and mental health of HS patients, and to determine the association of inflammatory arthritis in the context of other systemic inflammatory diseases (inflammatory bowel disease (IBD), rheumatoid arthritis (RA), etc.) in these two-patient population of psoriasis and HS.

5. Study to Analyze the Metabolic Environment in Preventing Atopic Dermatitis

   Rochester, Minn.

   The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as compared to age/sex and diet matched control children without atopic dermatitis, and to apply mass-spectrometry-based metabolomic approach to analyzing fecal, nasal, oral and skin samples from cases, in order to characterize their biochemical metabolic profiles by comparison with those of their controls.

6. C. Albicans during Early Life Predisposes Individuals to Atopy

   Rochester, Minn.

   The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis.

   We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations.

    

7. Serum Derived From Patient Donors With Paraneoplastic Pemphigus (PNP) to Be Used as a Positive Control for PNP Test

   Rochester, Minn.

   The purpose of this study is to obtain serum from patients with certain rare immunobullous diseases (e.g., paraneoplastic pemphigus, laminin-332 pemphigoid) to replenish a source of positive control for our clinical testing (e.g., Mayo test codes PNPAB, RSBV).  

   • To verify the performance characteristics of anti-Paraneoplastic Pemphigus (PNP) serum and validate its use as a positive control in PNP test.  

   • Serum from patients with PNP will be used for a positive control for the PNP test upon successful validation. 

   Background:  

   For various rare immunobullous diseases, detection of a circulating autoantibody is necessary for accurate diagnosis. As a CLIA requirement, every clinical test run requires positive and negative controls for quality control.  Currently, we use either archived sera or commercially available sera from patients with known relevant immunobullous diseases as a structural integrity positive control of rat bladder or transfected cells, which are the substrates for these indirect immunofluorescence tests.  

   While we have no difficulty locating negative control sera, it is challenging to source positive control sera, due to the rarity of these diseases. Specifically, commercial positive control serum is no longer available for purchase and only limited archived material is available. 

8. Skin Aging And Longevity Understanding Database (SALUD)

   Rochester, Minn.

   The purpose of this study is to identify and evaluate skin aging biomarkers based on clinical, phenotypic, histological, and molecular assessments.

9. Cutaneous Tissue Using Ex Vivo Fluorescence Confocal Microscopy

   Rochester, Minn.

   The purpose of this study, as a proof-of-concept, is to investigate whether ex vivo fluorescence microscopy can provide adequate visualization of cutaneous tissue for determination of non-melanoma skin cancer tumor presence in a sample of up to 250 residual skin specimens.

10. Tebentafusp Regimen Versus Investigator's Choice In Previously Treated Advanced Melanoma (TEBE-AM)

    Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The purpose of this study is to evaluate the effectiveness and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma.